Organon shelves contraceptive with 'natural' estrogen

2024-02-13

临床3期临床终止

Organon’s attempt to revive a once-rejected “natural” contraceptive is over, a spokesperson confirmed to Endpoints News. The Merck women’s health spinoff has terminated a Phase III trial for NOMAC-E2 early due to “business reasons,” the spokesperson said. The company said the decision was unrelated to the drug’s safety. NOMAC-E2 was developed by Theramex, a women’s health business that was once part of Merck KGaA and Teva. The candidate has been touted as a “natural” alternative to other contraceptives using synthetic estrogen, because it contains a version of the hormone that’s structurally identical to estrogen produced in the body.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构